Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
José María Prieto González & Carlos Vila Silván. (2021) Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports. Expert Review of Neurotherapeutics 21:5, pages 547-558.
Read now
Read now
Michael A Ueberall, Ute Essner & Gerhard HH Mueller-Schwefe. (2019) Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry. Journal of Pain Research 12, pages 1577-1604.
Read now
Read now
Yara Mouhamed, Andrey Vishnyakov, Bessi Qorri, Manpreet Sambi, SM Signy Frank, Catherine Nowierski, Anmol Lamba, Umrao Bhatti & Myron R Szewczuk. (2018) Therapeutic potential of medicinal marijuana: an educational primer for health care professionals. Drug, Healthcare and Patient Safety 10, pages 45-66.
Read now
Read now
Tilden Etges, Kari Karolia, Thomas Grint, Adam Taylor, Heather Lauder, Brian Daka & Stephen Wright. (2016) An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray. Therapeutics and Clinical Risk Management 12, pages 1667-1675.
Read now
Read now
Irene Moreno Torres, Antonio J Sanchez & Antonio Garcia-Merino. (2014) Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis. Expert Review of Neurotherapeutics 14:11, pages 1243-1250.
Read now
Read now
Articles from other publishers (13)
Mohammad Uzair, Hammad Qaiser, Muhammad Arshad, Saneela Tahseen & Shahid Bashir. 2023. Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases. Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases
187
216
.
Andrew Chan & Carlos Vila Silván. (2022) Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap. Neurodegenerative Disease Management 12:3, pages 141-154.
Crossref
Crossref
Victor Longoria, Hannah Parcel, Bameelia Toma, Annu Minhas & Rana Zeine. (2022) Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination. Biomedicines 10:3, pages 539.
Crossref
Crossref
Friedemann Paul & Carlos Vila Silván. (2021) Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity. Neurodegenerative Disease Management 11:2, pages 143-153.
Crossref
Crossref
Éamon Jones & Styliani Vlachou. (2020) A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment. Molecules 25:21, pages 4930.
Crossref
Crossref
Katja Akgün, Ute Essner, Cordula Seydel & Tjalf Ziemssen. (2019) Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies. Journal of Central Nervous System Disease 11, pages 117957351983199.
Crossref
Crossref
T. Henze, W. Feneberg, P. Flachenecker, D. Seidel, H. Albrecht, M. Starck & S. G. Meuth. (2017) Neues zur symptomatischen MS‑Therapie: Teil 2 – Gangstörung und SpastikWhat is new in symptomatic MS treatment: Part 2—gait disorder and spasticity. Der Nervenarzt 88:12, pages 1428-1434.
Crossref
Crossref
Gillian M. Keating. (2017) Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity. Drugs 77:5, pages 563-574.
Crossref
Crossref
F Patti, S Messina, C Solaro, M P Amato, R Bergamaschi, S Bonavita, R Bruno Bossio, V Brescia Morra, G F Costantino, P Cavalla, D Centonze, G Comi, S Cottone, M Danni, A Francia, A Gajofatto, C Gasperini, A Ghezzi, A Iudice, G Lus, G T Maniscalco, M G Marrosu, M Matta, M Mirabella, E Montanari, C Pozzilli, M Rovaris, E Sessa, D Spitaleri, M Trojano, P Valentino & M Zappia. (2016) Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. Journal of Neurology, Neurosurgery & Psychiatry 87:9, pages 944-951.
Crossref
Crossref
Laura Ferrè, Arturo Nuara, Giulia Pavan, Marta Radaelli, Lucia Moiola, Mariaemma Rodegher, Bruno Colombo, Ignacio Juan Keller Sarmiento, Vittorio Martinelli, Letizia Leocani, Filippo Martinelli Boneschi, Giancarlo Comi & Federica Esposito. (2015) Efficacy and safety of nabiximols (Sativex®) on multiple sclerosis spasticity in a real-life Italian monocentric study. Neurological Sciences 37:2, pages 235-242.
Crossref
Crossref
Uwe K. Zettl, Paulus Rommer, Petra Hipp & Robert Patejdl. (2015) Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Therapeutic Advances in Neurological Disorders 9:1, pages 9-30.
Crossref
Crossref
G. Coghe, M. Pau, F. Corona, J. Frau, L. Lorefice, G. Fenu, G. Spinicci, E. Mamusa, L. Musu, S. Massole, R. Massa, M. G. Marrosu & E. Cocco. (2015) Walking improvements with nabiximols in patients with multiple sclerosis. Journal of Neurology 262:11, pages 2472-2477.
Crossref
Crossref
Katja Schmitz, Julia Barthelmes, Leonie Stolz, Susanne Beyer, Olaf Diehl & Irmgard Tegeder. (2015) “Disease modifying nutricals” for multiple sclerosis. Pharmacology & Therapeutics 148, pages 85-113.
Crossref
Crossref